Jay Steingrub to Risk
This is a "connection" page, showing publications Jay Steingrub has written about Risk.
Connection Strength
0.043
-
Mitchell SC, Steingrub J. The changing clinical trials scene: the role of the IRB. IRB. 1988 Jul-Aug; 10(4):1-5.
Score: 0.018
-
Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med. 2005 Aug; 33(8):1741-8.
Score: 0.015
-
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 08; 344(10):699-709.
Score: 0.011